Celldex Reports Results from Phase 2 Study of Barzolvolimab in Prurigo Nodularis
Go back to Celldex Reports Results from Phase 2 Study of Barzolvolimab in Prurigo Nodularis| CELLDEX THERAPEUTICS, Inc. (NASDAQ: CLDX) | Delayed: 39.20 -0.48 (1.21%) | |||||
|---|---|---|---|---|---|---|
| Previous Close | $39.68 | 52 Week High | $18.62 | |||
| Open | $38.78 | 52 Week Low | $2.85 | |||
| Day High | $39.20 | P/E | N/A | |||
| Day Low | $38.50 | EPS | $-1.02 | |||
| Volume | 27,298 | |||||
